Second Generation Catecholomethyltransferase Inhibitors

Little attention was devoted to COMT inhibitors for the treatment of PD during the mid-1980s, but the 1990s ushered in renewed interest in the potential clinical usefulness of these compounds. This renewed attention was prompted by the development of a "second generation" of COMT inhibitors, substances that were more potent, more selective, and less toxic than their predecessors. Several nitrocatechol compounds, eventually bearing the names nitecapone, entacapone, and tolcapone, became the focus of laboratory and clinical study.

Was this article helpful?

0 0

Post a comment